The Preoperative Neutrophil-To-Lymphocyte Ratio Is a Novel Immune Parameter for the Prognosis of Esophageal Basaloid Squamous Cell Carcinoma
Fig 2
Univariate analysis of overall survival (OS) and recurrence-free survival (RFS).
(A) The median OS of the low neutrophil–to–lymphocyte ratio (NLR; ≤1.77) group was 51.0 months, which was significantly longer than the 31.0 months observed in the high NLR (>1.77) group. (B) A significant difference in median OS was also observed between the low (≤12.31) neutrophil–to–monocyte ratio (NMR) group and high (>12.31) NMR group (43.0 vs. 31.0 months). (C) The median OS of the low (≤40.0 g/L) albumin groupwas 26.0 months, which was shorter than the 42.0 months observed in the high (>40.0 g/L) albumin group. (D) The median recurrence-free survival (RFS) was 44.0 months for the low (≤1.77) NLR group and 14.0 months for the high (> 1.77) NLR group. The median RFS in patients with a high NMR or albumin level was numerically, but not significantly, greater than patients with a low NMR (E) or albumin level (F).